10/750,326

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2396	((514/81) or (514/257) or (514/266.2) or (514/266.3) or (514/267)).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/16 16:18
L2	2709	((544/244) or (544/250) or (544/284) or (544/285)).CCLS.	US-PGPUB; USPAT; USOCR	OR	OFF	2007/03/16 16:18
L3	3940	L1 or L2	US-PGPUB; USPAT	OR	OFF	2007/03/16 16:19
L4	976	L3 and (dioxo or dione)	US-PGPUB; USPAT	OR	ON	2007/03/16 16:19

10/ 750,326

Connecting via Winsock to STN

Search for species in claim 18

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:57:52 ON 16 MAR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:58:05 ON 16 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2007 HIGHEST RN 926596-82-9
DICTIONARY FILE UPDATES: 15 MAR 2007 HIGHEST RN 926596-82-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10750326a.str





chain nodes :
11 12 13
ring nodes :
1 2 3 4 5 6 7 8 9 10 14 15 16 17 18
chain bonds :
7-11 9-12 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 14-15 14-18 15-16 16-17 17-18

exact/norm bonds :
5-7 6-10 7-8 7-11 8-9 9-10 9-12 10-13
exact bonds :
13-14 14-15 14-18 15-16 16-17 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 14 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 14:58:44 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1995 TO ITERATE

100.0% PROCESSED 1995 ITERATIONS 43 ANSWERS
SEARCH TIME: 00.00.01

L2 43 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'HCAPLUS' ENTERED AT 14:58:51 ON 16 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

10/ 750,326

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Mar 2007 VOL 146 ISS 13
FILE LAST UPDATED: 15 Mar 2007 (20070315/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l2
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s l2
L3 3 L2

=> d his

(FILE 'HOME' ENTERED AT 14:57:52 ON 16 MAR 2007)

FILE 'REGISTRY' ENTERED AT 14:58:05 ON 16 MAR 2007
L1 STRUCTURE UPLOADED
L2 43 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 14:58:51 ON 16 MAR 2007
L3 3 S L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:589543 HCAPLUS
DOCUMENT NUMBER: 141:140460
TITLE: Quinazolinedione and indole amino acid derivatives as inhibitors of phosphatases, particularly SHP-2, and their pharmaceutical compositions, preparation, and use in the treatment of autoimmune diseases, proliferative diseases, angiogenic disorders, and cancer.
INVENTOR(S): Saunders, Jeffrey O.; Miknis, Gregory F.; Buckmelter, Alexandre J.; Hunt, Kevin W.; Blake, James F.; Vigers, Guy P. A.; Sun, Xicheng
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004060878 A2 20040722 WO 2003-US41661 20031231
WO 2004060878 A3 20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2511925 A1 20040722 CA 2003-2511925 20031231
AU 2003300114 A1 20040729 AU 2003-300114 20031231
US 2004186116 A1 20040923 US 2003-750326 20031231
EP 1583747 A2 20051012 EP 2003-800372 20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006514658 T 20060511 JP 2004-565845 20031231
PRIORITY APPLN. INFO.: US 2002-437567P P 20021231
WO 2003-US41661 W 20031231

PG Pub.

OTHER SOURCE(S): MARPAT 141:140460
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to compds. I and II, which inhibit phosphatases (no data), particularly SHP-2 (src homol. 2-containing protein tyrosine phosphatase), to compns. thereof, and to methods of using those compds. and compns. for treating diseases [wherein: (I) A, A' = (optional) atoms to complete (un)substituted (hetero)aryl ring; n = 0-4; R1 = H, (un)substituted hydroxyaliph., aminoaliph., carboxyaliph., carbamoylaliph., or arylaliph.; R2 = (un)substituted aliphatic, (hetero)arylaliph., (hetero)cycloaliph.-aliphatic; R3, R4 = H or a wide variety of independent substituents and sidechains, provided that both R3 and R4 ≠ H simultaneously, that when R3 = H then R4 ≠ Cl, and that when R4 = H then R3 ≠ SMe or NHAc; (II) X = (CH2)1-3, Y = O, S, NH, N-aliphatic; Z = H, aliphatic; q = 0 or 1; Rx, Ry, Rz = wide variety of optional, independent substituents and sidechains]. The compds. are useful (no data) for treating autoimmune diseases, proliferative diseases, angiogenic disorders, or cancers. Approx. 40 compds., including members of both I and II, were prepared and characterized. For instance, 4-amino-2-nitrobenzoic acid was converted in 5 steps to 4-(acetylamino)-2-[(furan-2-ylmethyl)amino]benzoic acid, which was N-linked via phosgene to hydroxymethyl polystyrene resin. The resin-bound acid was cyclized with aspartic acid di-tert-Bu ester HCl, and the quinazolinedione product was cleaved from the resin with TFA in MeOH and deprotected with 50% TFA in DCM, to give invention compound III.

IT 725238-83-5P 725238-84-6P 725238-85-7P
725238-86-8P 725238-87-9P 725238-88-0P
725238-89-1P 725238-90-4P 725238-91-5P
725238-92-6P 725238-93-7P 725238-94-8P
725238-95-9P 725238-96-0P 725238-97-1P
725238-98-2P 725238-99-3P 725239-00-9P
725239-01-0P 725239-02-1P 725239-03-2P
725239-04-3P 725239-29-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of quinazolinedione and indole amino acid derivs. as SHP-2 inhibitors for treatment of autoimmune, proliferative, angiogenic, and neoplastic diseases)

RN 725238-83-5 HCAPLUS
CN Butanedioic acid, [7-(acetylamino)-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-84-6 HCAPLUS
CN Butanedioic acid, [6-chloro-1,4-dihydro-1-[(5-methyl-2-furanyl)methyl]-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-85-7 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-6-(methylsulfonyl)-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-86-8 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-6-(phenylsulfonyl)-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-87-9 HCAPLUS
CN Butanedioic acid, [7-(benzoylamino)-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-88-0 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-7-[(phenylsulfonyl)amino]-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-89-1 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-6-(2-propenyloxy)-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-90-4 HCAPLUS
CN Butanedioic acid, [6-[(4-chlorophenyl)sulfonyl]-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-91-5 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-6-methyl-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-92-6 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-6-(phenylthio)-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-93-7 HCAPLUS
CN Butanedioic acid, [6-[(4-chlorophenyl)sulfinyl]-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-94-8 HCAPLUS
CN Butanedioic acid, [6-chloro-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-95-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(2-furanylmethyl)-1,4-dihydro-6-(2-naphthalenyloxy)-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-96-0 HCAPLUS
CN Butanedioic acid, [6-([1,1'-biphenyl]-4-yloxy)-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-97-1 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-6-(methylsulfinyl)-2,4-dioxo-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725238-98-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-6-(2-propenyloxy)- (9CI) (CA INDEX NAME)



RN 725238-99-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-([1,1'-biphenyl]-4-yloxy)-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-00-9 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1-(2-furanylmethyl)-1,4-dihydro-α-(1H-indol-3-ylmethyl)-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-01-0 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-[(4-chlorophenyl)thio]-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-02-1 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-([1,1'-biphenyl]-4-yloxy)-1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 725239-03-2 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-[(4-chlorophenyl)thio]-1-(2-furanylmethyl)-1,4-dihydro-α-(1H-indol-3-ylmethyl)-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-04-3 HCAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(2-furanylmethyl)-1,4-dihydro-α-(1H-indol-3-ylmethyl)-6-(methylthio)-2,4-dioxo-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-29-2 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-2,4-dioxo-6-[(phenylsulfonyl)amino]-3(2H)-quinazolinyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 725239-42-9P 725239-44-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(intermediate; preparation of quinazolinedione and indole amino acid derivs. as SHP-2 inhibitors for treatment of autoimmune, proliferative, angiogenic, and neoplastic diseases)

RN 725239-42-9 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-6-(methylthio)-2,4-dioxo-3(2H)-quinazolinyl]-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 725239-44-1 HCAPLUS
CN Butanedioic acid, [1-(2-furanylmethyl)-1,4-dihydro-6-(methylsulfonyl)-2,4-dioxo-3(2H)-quinazolinyl]-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:57304 HCAPLUS
DOCUMENT NUMBER: 140:127844
TITLE: Preparation of fluorinated silica gel support material for palladium catalyzed coupling reactions
INVENTOR(S): Bannwarth, Willi; Tzschucke, Carl Christoph; Glatz, Heiko; Schwinn, Dominik
PATENT ASSIGNEE(S): Albert-Ludwigs-Universitaet Freiburg, Germany
SOURCE: Ger., 19 pp.
CODEN: GWXXAW
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10235225	B3	20040122	DE 2002-10235225	20020801
WO 2004013068	A1	20040212	WO 2003-EP7592	20030714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003250053	A1	20040223	AU 2003-250053	20030714
PRIORITY APPLN. INFO.:			DE 2002-10235225 A	20020801
			WO 2003-EP7592 W	20030714

OTHER SOURCE(S): CASREACT 140:127844

AB The title support materials were synthesized and their use for palladium catalyzed coupling reactions is described. Thus, Rh(PPh3)3Cl-catalyzed silylation of HSi(CH2CH2C6F13)3 with triethoxyvinylsilane in THF gave 54% (EtO)3SiCH2CH2Si(CH2CH2C6F13)3 which on treatment with activated silica gel gave title support material. [(4-F17C8CH2CH2C6H4)3P]2PdCl2-catalyzed Suzuki reaction of 4-BrC6H4NO2 with PhB(OH)2 in the presence of above prepared fluorinated support material in DME gave quant. yield of 4-PhC6H4NO2. Also perfluoro-tagged benzyl alc. adsorbed on fluorous reversed-phase silica gel derivative via fluorous-fluorous interactions was prepared and used in the combinatorial synthesis of quinazolinediones by a fluorous biphasic concept without perfluorinated solvents.

IT 531504-05-9P 531504-06-0P 531504-07-1P
531504-08-2P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(preparation of perfluoro-tagged benzyl alc. adsorbed on fluorous reversed-phase silica gel derivative via fluorous-fluorous interactions for combinatorial synthesis of quinazolinediones by a fluorous biphasic concept without perfluorinated solvents)

RN 531504-05-9 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 1,3-bis(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 531504-06-0 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 1-(2-furanylmethyl)-3-(phenylmethyl)- (9CI)

(CA INDEX NAME)



RN 531504-07-1 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-(3,4-dimethoxyphenyl)-1-(2-furanylmethyl)-(9CI) (CA INDEX NAME)



RN 531504-08-2 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-[2-(4-chlorophenyl)ethyl]-1-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:127066 HCAPLUS
DOCUMENT NUMBER: 138:401691
TITLE: Multistep parallel synthesis of quinazoline-2,4-diones by a fluorous biphasic concept without perfluorinated

solvents

AUTHOR(S): Schwinn, Dominik; Glatz, Heiko; Bannwarth, Willi
CORPORATE SOURCE: Inst. Organische Chemie and Biochemie, Univ. Freiburg, Freiburg, D-79104, Switz.

SOURCE: Helvetica Chimica Acta (2003), 86(1), 188-195
CODEN: HCACAV; ISSN: 0018-019X
PUBLISHER: Verlag Helvetica Chimica Acta
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:401691

GI



I

AB Based on perfluoro-tagged benzyl alc. adsorbed via fluorous-fluorous interactions on fluorous reversed-phase silica gel (FRPSG), multistep synthesis a small library of quinazoline-2,4-diones, e.g. I, from perfluorinated benzyl alc. via cyclization was achieved. The whole reaction sequence runs without isolation of intermediates and most importantly, without the need of perfluorinated solvents.

IT 531504-05-9P 531504-06-0P 531504-07-1P
531504-08-2P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial library of quinazolinediones via fluorous-fluorous interactions on fluorous reversed-phase silica gel via adsorption and cyclization)

RN 531504-05-9 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 1,3-bis(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 531504-06-0 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 1-(2-furanylmethyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 531504-07-1 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-(3,4-dimethoxyphenyl)-1-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



RN 531504-08-2 HCAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-[2-(4-chlorophenyl)ethyl]-1-(2-furanylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:57:52 ON 16 MAR 2007)